GCCL participated in the World Vaccine Congress Washington 2026,
held in Washington, D.C. from March 30 to April 2.

World Vaccine Congress is one of the leading global events where companies, research institutions, and experts in the vaccine industry come together
to share the latest trends in R&D, technologies, clinical strategies, and partnership opportunities.

At this year’s event, GCCL had the opportunity to engage with many industry professionals
through a variety of activities, including exhibiting at our booth, 
presenting a research poster, holding global partnering meetings, and attending program sessions.

Today, we would like to share a glimpse of our experience on site.

Throughout the event, GCCL operated an independent booth and
introduced our specialized analytical services for vaccine and therapeutic development
to global pharmaceutical and biotech companies, research institutions, and vaccine development stakeholders.

At the booth, we highlighted GCCL’s capabilities in vaccine and infectious disease analysis, including
neutralizing antibody analysis, immunogenicity testing, biomarker analysis,
 Central Lab services, and bioanalytical services to support vaccine development.

In particular, GCCL introduced its strengths as a reliable partner for global clinical trials, built on a
GCLP-based clinical sample testing system and extensive experience in performing a wide range of analyses required throughout the vaccine development process.

Another meaningful outcome of the event was the opportunity
to communicate directly with a wide range of industry professionals and
gain a more concrete understanding of current market interests and actual analytical needs.

At this year’s event, GCCL also presented a research poster developed by Research Team 2:
Development and Optimization of an Automated Focus Reduction Neutralization Test (FRNT) Assay for Evaluating RSV Neutralizing Antibody Titers

FRNT is an important analytical method used to assess viral neutralizing activity
during vaccine and antibody therapeutic development,
where accuracy and reproducibility are especially critical.

Through this poster, GCCL introduced the development and optimization process of an
automated FRNT assay for RSV, demonstrating the potential
for more efficient and consistent analytical performance.

This presentation reflected GCCL’s ongoing efforts to strengthen its capabilities beyond routine testing,
particularly in assay development and optimization for vaccine development.

On site, the poster also led to technical discussions with attendees and drew interest in
GCCL’s expertise in vaccine-related analysis.

Another important part of WVC was the wide range of partnering meetings held throughout the event.

During the congress, GCCL met with representatives from various companies and institutions to discuss
development directions in the vaccine and infectious disease fields, 
analytical needs, and potential areas for future collaboration.

Because each company is at a different stage of development and requires highly specific analytical support,
even short meetings provided valuable insights.

These partnering meetings gave GCCL a meaningful opportunity
to better understand the needs of the global market and further consider
how we can support clients in more practical and tailored ways.

In particular, meeting stakeholders from North America, Europe, and Asia
helped GCCL expand business opportunities and identify
broader points of connection within the global vaccine development ecosystem.

During the event, GCCL also signed an MOU with VisMederi, 
an Italy-based analytical institution specializing in vaccines and infectious diseases.

VisMederi has strong expertise in the vaccine and infectious disease field, and this agreement marked a
meaningful starting point for expanding global collaboration 
based on the strengths of both organizations.

Through this MOU, GCCL will contribute its experience and operational capabilities in the Asia region,
 while VisMederi brings its expertise and network in Europe, creating opportunities for mutual synergy.

At a time when global collaboration is becoming increasingly important in the vaccine and infectious field,
this agreement is particularly meaningful as it establishes a foundation
for closer cooperation between the two organizations.

The signing ceremony held during the event was also a memorable moment for GCCL, raising expectations for
the possibilities the two organizations may create together going forward.

In addition to exhibiting and holding meetings, GCCL also attended various program sessions to explore
the latest trends in the global vaccine industry.

At the event, a wide range of topics were covered, including next-generation vaccine platforms,
infectious disease response strategies, clinical development and regulatory issues, immune response evaluation, pandemic preparedness, and global collaboration.

It was a valuable opportunity to see firsthand
which technologies and strategies are drawing attention in today’s rapidly evolving vaccine landscape.

Following these discussions and industry movements on site was also highly meaningful for GCCL,
as it helps us better understand customer needs and
further advance our service direction and technical capabilities.

Overall, participating in World Vaccine Congress Washington 2026 was a valuable experience for GCCL.

It allowed us to engage directly with stakeholders across the global vaccine industry,
better understand on-the-ground needs, and
introduce both our analytical expertise and collaboration potential.

GCCL will continue to provide reliable analytical services across a wide range of global clinical trial areas, including vaccines and infectious diseases,
and remain a trusted partner supporting our clients’ successful development programs.

We will continue to serve as a trusted clinical trial partner for our clients.
To learn more about GCCL, please click the banner below.